Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Patentability of Chemical Selection Inventions
| Patentability of Chemical Selection Inventions |
| Autore | Ahn Hyewon |
| Edizione | [First edition.] |
| Pubbl/distr/stampa | La Vergne : , : e-book, , 2024 |
| Descrizione fisica | 1 online resource (75 pages) : illustrations |
| Collana | Munich Intellectual Property Law Center - MIPLC |
| Soggetto topico |
Drugs
Patent laws and legislation Conflict of laws - Patents Drug development Olanzapine Citalopram |
| Soggetto non controllato |
Markenrecht
Urheberrecht / Gewerblicher Rechtsschutz und Medienrecht Gewerblicher Rechtsschutz |
| ISBN | 3-8452-3218-8 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISA-996344238503316 |
Ahn Hyewon
|
||
| La Vergne : , : e-book, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Patentability of Chemical Selection Inventions
| Patentability of Chemical Selection Inventions |
| Autore | Ahn Hyewon |
| Edizione | [First edition.] |
| Pubbl/distr/stampa | Nomos Verlagsgesellschaft mbH & Co. KG, 2011 |
| Descrizione fisica | 1 online resource (75 pages) : illustrations |
| Collana | Munich Intellectual Property Law Center - MIPLC |
| Soggetto topico |
Drugs
Patent laws and legislation Conflict of laws - Patents Drug development Olanzapine Citalopram |
| ISBN |
9783845232188
3845232188 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910297034703321 |
|
Ahn Hyewon
|
||
| Nomos Verlagsgesellschaft mbH & Co. KG, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Second generation patents in pharmaceutical innovation / / Hyewon Ahn
| Second generation patents in pharmaceutical innovation / / Hyewon Ahn |
| Autore | Ahn Hyewon |
| Edizione | [1. edition.] |
| Pubbl/distr/stampa | Baden-Baden, [Germany] : , : Nomos, , 2014 |
| Descrizione fisica | 1 online resource (355 p.) |
| Disciplina | 338.4/76151 |
| Collana | MIPLC Studies |
| Soggetto topico |
Drugs
Drugs - Law and legislation Drug development Patent laws and legislation |
| Soggetto genere / forma | Patents. |
| ISBN | 3-8452-5086-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; I. INTRODUCTION; A. Overview; B. Outline of the dissertation; C. Scope of the dissertation; II. PHARMACEUTICAL INVENTIONS, INNOVATIONS & PRODUCTS; A. Cumulative nature of inventions; 1. Basic and second generation inventions; a) Improvement inventions; b) Selection inventions; B. Inventions and innovations in pharmaceutical field; 1. Inventions and patents in pharmaceutical field; a) Product invention and the absolute character of its protection; b) Hierarchy of pharmaceutical patents; 2. Innovations in pharmaceutical field; a) Invention v. innovation
b) NMEs as the core of pharmaceutical innovation C. Second generation inventions and patents in pharmaceuticals; 1. Product inventions and patents; a) Species selection inventions; Markush type claim; A species claim; b) Optical isomers; c) Crystalline forms; d) Metabolites and prodrugs; e) Esters and salts; f) Dosage forms; g) Combinations of active ingredients; 2. Use inventions; a) New Use/New method of treatment; b) Dosage regime; 3. Process inventions; a) Process; b) Intermediates; D. Pharmaceutical products in the market 1. New medical entities, new molecular entities 2. Similar or equivalent "me-too" products; 3. Second generation products; 4. Generic drugs; E. Summary; III. SPECIFICITIES IN PHARMACEUTICALS AND RECENT DEVELOPMENTS; A. Innovating and inventing in pharmaceutical industry; 1. Specificities in the drug development process; a) Highly regulated industry; b) R&D - a costly and lengthy road to a medicine; c) Uncertainties in post-invention development; (1) Scientific uncertainty: Unpredictability of substances; (2) Regulatory and market uncertainties; d) Information rich chemicals 2. Specificities in the market for pharmaceuticals a) Imitation with negligible cost and much reduced risk; b) Prescription based purchase: A disconnection between choosers and payers; c) Information asymmetry and high loyalty to a medicine; d) Pricing; 3. Specificities of the patent protection for pharmaceuticals; a) Patent protection for industrial technologies; b) Patent protection in the pharmaceutical industry; B. Challenges and overcoming efforts; 1. Decreased R&D productivity; 2. Dearth of new medical entities; a) Significance of NMEs; b) Decreased number of NMEs c) Potential reasons for the decrease (1) Decrease in solvable scientific problems; (2) Stringent safety regulations; (3) Problem of over-disclosure; (4) Early and numerous abandonments of potential candidates; 3. Patent cliffs of blockbuster medications; 4. Frequent merger and acquisitions (M&As) and in-licensing; 5. Drastic increase of second generation inventions; a) Life cycle management or evergreening; b) Drastic increase of this activity supported by the number of second generation patents; C. Summary; IV. STANDARDS OF PATENTABILITY FOR PHARMACEUTICAL SELECTION INVENTIONS A. Novelty and anticipation |
| Record Nr. | UNISA-996344234703316 |
|
Ahn Hyewon
|
||
| Baden-Baden, [Germany] : , : Nomos, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Second generation patents in pharmaceutical innovation / / Hyewon Ahn
| Second generation patents in pharmaceutical innovation / / Hyewon Ahn |
| Autore | Ahn Hyewon |
| Edizione | [1. edition.] |
| Pubbl/distr/stampa | Baden-Baden, [Germany] : , : Nomos, , 2014 |
| Descrizione fisica | 1 online resource (355 p.) |
| Disciplina | 338.4/76151 |
| Collana | MIPLC Studies |
| Soggetto topico |
Drugs
Drugs - Law and legislation Drug development Patent laws and legislation |
| Soggetto genere / forma | Patents. |
| ISBN | 3-8452-5086-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; I. INTRODUCTION; A. Overview; B. Outline of the dissertation; C. Scope of the dissertation; II. PHARMACEUTICAL INVENTIONS, INNOVATIONS & PRODUCTS; A. Cumulative nature of inventions; 1. Basic and second generation inventions; a) Improvement inventions; b) Selection inventions; B. Inventions and innovations in pharmaceutical field; 1. Inventions and patents in pharmaceutical field; a) Product invention and the absolute character of its protection; b) Hierarchy of pharmaceutical patents; 2. Innovations in pharmaceutical field; a) Invention v. innovation
b) NMEs as the core of pharmaceutical innovation C. Second generation inventions and patents in pharmaceuticals; 1. Product inventions and patents; a) Species selection inventions; Markush type claim; A species claim; b) Optical isomers; c) Crystalline forms; d) Metabolites and prodrugs; e) Esters and salts; f) Dosage forms; g) Combinations of active ingredients; 2. Use inventions; a) New Use/New method of treatment; b) Dosage regime; 3. Process inventions; a) Process; b) Intermediates; D. Pharmaceutical products in the market 1. New medical entities, new molecular entities 2. Similar or equivalent "me-too" products; 3. Second generation products; 4. Generic drugs; E. Summary; III. SPECIFICITIES IN PHARMACEUTICALS AND RECENT DEVELOPMENTS; A. Innovating and inventing in pharmaceutical industry; 1. Specificities in the drug development process; a) Highly regulated industry; b) R&D - a costly and lengthy road to a medicine; c) Uncertainties in post-invention development; (1) Scientific uncertainty: Unpredictability of substances; (2) Regulatory and market uncertainties; d) Information rich chemicals 2. Specificities in the market for pharmaceuticals a) Imitation with negligible cost and much reduced risk; b) Prescription based purchase: A disconnection between choosers and payers; c) Information asymmetry and high loyalty to a medicine; d) Pricing; 3. Specificities of the patent protection for pharmaceuticals; a) Patent protection for industrial technologies; b) Patent protection in the pharmaceutical industry; B. Challenges and overcoming efforts; 1. Decreased R&D productivity; 2. Dearth of new medical entities; a) Significance of NMEs; b) Decreased number of NMEs c) Potential reasons for the decrease (1) Decrease in solvable scientific problems; (2) Stringent safety regulations; (3) Problem of over-disclosure; (4) Early and numerous abandonments of potential candidates; 3. Patent cliffs of blockbuster medications; 4. Frequent merger and acquisitions (M&As) and in-licensing; 5. Drastic increase of second generation inventions; a) Life cycle management or evergreening; b) Drastic increase of this activity supported by the number of second generation patents; C. Summary; IV. STANDARDS OF PATENTABILITY FOR PHARMACEUTICAL SELECTION INVENTIONS A. Novelty and anticipation |
| Record Nr. | UNINA-9910297050903321 |
|
Ahn Hyewon
|
||
| Baden-Baden, [Germany] : , : Nomos, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||